The company, which is developing treatments for visual deterioration, has now raised $75m in its first two equity rounds, with Novo Ventures co-leading its series B.
US-based pharmaceutical company PanOptica has secured $45m in series B financing from investors including Novo Ventures, which acts as the corporate venturing arm of Denmark-based healthcare company Novo.
Novo, which participated in the round as a new investor, co-led the round with existing backer Third Rock Ventures, while SV Life Sciences also participated. Third Rock and SV previously provided $30m for PanOptica’s 2011 series A round.
Founded in 2009 with seed financing from SV, PanOptica develops therapies for ophthalmology, and…
